Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Other

Bright Minds to discuss BMB-101 phase 2 trial Jan. 6

By The Northwire Desk — AI Analysis Jan 05, 2026 · 20:48 DRUG · 104 Bright Minds Biosciences Inc
DRUG · Price

Executive Summary

  • Bright Minds Biosciences Inc. will host a live webcast and conference call on Tuesday, Jan. 6, 2026 at 8 a.m. ET to present the top‑line results of the Phase 2 BMB‑101 trial in drug‑resistant absence seizures and developmental & epileptic encephalopathies.
  • The presentation will include a data discussion followed by a Q&A session; participants can submit questions via the webcast “questions” tab.
  • A replay of the event will be posted on Bright Minds’ investor website after the call.

Key Details

  • Event: Conference call & live webcast to disclose Phase 2 trial results for BMB‑101.
  • Date/Time: Jan. 6, 2026, 8:00 a.m. Eastern Time.
  • Access: Live stream via the “Investors” → “Events and Presentations” section of Bright Minds’ website; replay available thereafter.
  • Agenda: Presentation of trial data → Question‑and‑Answer session (questions submitted through webcast interface).
  • Trial Focus: Patients with drug‑resistant absence seizures and developmental & epileptic encephalopathies.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from Bright Minds Biosciences Inc

Jan 09, 2026 · 18:00

Bright Minds closes $175-million (U.S.) public offering

Financings Jan 09, 2026 · 11:56

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Financings Jan 08, 2026 · 04:40

Bright Minds prices shares of offering at $90 each

Financings Jan 07, 2026 · 21:33

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Financings Jan 06, 2026 · 19:32

Bright Minds arranges $10M (U.S.) public offering

Financings Jan 06, 2026 · 16:35

Bright Minds' BMB-101 phase 2 shows seizure declines

Other